Home » Archive by Category

News

Original content and news from BioSpace, Xconomy, Marketwire and other sources, specific to the region.

Autism Early Detection Program Expands

September 10, 2014 – 9:00 am | Edit Post

Autism spectrum disorder (ASD) is now estimated to impact one in every 68 children born in the United States. A new 5-year, $5.1 million grant from the National Institute of Mental Health (NIMH) seeks expand a program developed by researchers at Univer…

Avelas Closes Round, Advancing Biologic That Illuminates Breast Cancer

September 10, 2014 – 5:00 am | Edit Post
Avelas Closes Round, Advancing Biologic That Illuminates Breast Cancer

San Diego’s Avelas Biosciences, which is developing a fluorescing peptide to illuminate cancerous tissue during breast surgery, says today it has closed the second tranche of its Series B round,…

[[Click headline to continue reading.]]

An Intriguing Program Takes on Tropical Diseases—But Not Ebola

September 10, 2014 – 3:30 am | Edit Post
An Intriguing Program Takes on Tropical Diseases—But Not Ebola

On August 28, Anthony Fauci, the U.S. National Institutes of Health’s top infectious disease specialist, announced a major trial in concert with GlaxoSmithKline (NYSE: GSK) to test new Ebola…

[[Click headline to continue reading.]]

Simple method turns human skin cells into immune-fighting white blood cells

September 9, 2014 – 5:00 pm | Edit Post

LA JOLLA—For the first time, scientists have turned human skin cells into transplantable white blood cells, soldiers of the immune system that fight infections and invaders. The work, done at the Salk Institute, could let researchers create therapies that introduce into the body new white blood cells capable of attacking diseased or cancerous cells or augmenting immune responses against other disorders.

ViaCyte starts diabetes trial

September 9, 2014 – 3:16 pm | Edit Post

ViaCyte starts human testing of a first-ever diabetes treatment derived from stem cells.

SGB Reports Success With Crop; Co. Closes $11M Series C Financing Round

September 9, 2014 – 3:13 pm | Edit Post

SGB Inc., a San Diego-based agricultural biotechnology and seed company, closed an $11 million Series C financing round.

Clinical Trial To Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes

September 9, 2014 – 3:00 pm | Edit Post

Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a …

Jatropha grower SGB raises $11 million

September 9, 2014 – 2:40 pm | Edit Post

Saying its high-yield jatropha is ready to sell, biotech SGB has raised $11 million.

After Restructuring, SGB Raises $11M for Jatropha Commercialization

September 9, 2014 – 2:31 pm | Edit Post
After Restructuring, SGB Raises $11M for Jatropha Commercialization

San Diego-based SGB, the agricultural biotech previously known as SG Biofuels, says today it has raised $11 million in a Series C round of financing that will be used to drive its revised…

[[Click headline to continue reading.]]

UC San Diego Named Nation’s 8th Best Public University by U.S. News and World Report

September 8, 2014 – 9:10 pm | Edit Post
UC San Diego Named Nation’s 8th Best Public University by U.S. News and World Report

The University of California, San Diego is ranked the 8th best public university in the nation by U.S. News & World Report. The publication’s 2015 Best Colleges guidebook, released today, ranks UC San Diego 37th best university in the U.S. among more than 200 public, private and for-profit institutions.